Inozyme Pharma, Inc.

NasdaqGS INZY

Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 23.66 M

Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities is USD 23.66 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -79.15% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 113.45 M, a 55.84% change year over year.
Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 72.80 M, a 18,862.63% change year over year.
Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -388.00 K, a -100.26% change year over year.
Inozyme Pharma, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 150.81 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: INZY

Inozyme Pharma, Inc.

CEO	Dr. Douglas A. Treco Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Summer Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years